17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure
Disclosed are compounds of formula (I), wherein X, Y, Z are annular atoms comprised in a five-membered carbocyclic or heterocyclic ring, selected from the group consisting of CH, NH, N, O, S; said carbocyclic or heterocyclic ring being optionally substituted with amino (C 1 -C 4 ) linear or branched alkyl or guanidine or guanidino (C 1 -C 4 ) linear or branched alkyl; with the proviso that the heterocycle ring is not furyl; n is 0 or 1; R is H or OH; the dotted line represents an optional double bond C═C; the thick line represents a bond in the β configuration; the wavy line represents a bond both in the α and β configuration; their enantiomeric and/or diastereomeric mixtures, their pharmaceutically acceptable salts, their solvates, hydrates; their metabolite and metabolic precursors. The compounds of formula (I) are for use as medicaments, in particular for the treatment of acute or chronic heart failure. Oral administration is also possible.
1. Compounds of formula (I)
wherein X, Y, Z are annular atoms comprised in a five-membered carbocyclic or heterocyclic ring, selected from the group consisting of CH, NH, N, O, S; and wherein:
n is 0 or 1 and said heterocyclic ring selected from the group consisting of imidazolyl, pyrazolyl, thiazolyl, isoxazolyl, and the corresponding dihydro- and tetrahydro derivatives;
R is H or OH; and
the dotted line represents an optional double bond C=C; the thick line represents a bond in the β configuration; the wavy line represents a bond both in the α and β configuration; or
the pharmaceutically acceptable salts, solvates, or hydrates thereof.
2. Compounds according to claim 1 , wherein the heterocycle group in position 17β is substituted by an amino(C 1 -C 4 ) linear or branched alkyl or guanidine or guanidino (C 1 -C 4 ) linear or branched alkyl.
3. Compounds according to claim 1 , wherein R is beta OH.
4. Compounds according to claim 1 , wherein the symbol n is 0.
5. Compounds according to claim 1 , wherein the symbol n is 1 and there is a single or double bond between the androstane skeleton and the 17β-heterocyclyl or carbocyclyl ring.
6. Compounds according to claim 1 , selected from the group consisting of:
3β-hydroxy-5β-10β-methyl-13β-methyl-14β-hydroxy-17β-(imidazol-4-yl)androstane;
3β-hydroxy-5β-10β-methyl-13β-methyl-14β-hydroxy-17β-(2-guanidino-thiazol-4-yl)androstane;
3β-hydroxy-5β-10β-methyl-12β-hydroxy-13β-methyl-14β-hydroxy-17β-(imidazol-4-yl)androstane;
3β-hydroxy-5β-10β-methyl-12β-hydroxy-13β-methyl-14β-hydroxy-17β-(2-guanidino-thiazol-4-yl)androstane;
3β-hydroxy-5β-10β-methyl-13β-methyl-14β-hydroxy-17β-(N-(3-aminopropyl)-imidazol-4-yl)androstane;
3β-hydroxy-5β-10β-methyl-13β-methyl-14β-hydroxy-17β-(pyrazol-3-yl)androstane;
3β-hydroxy-5β-10β-methyl-13β-methyl-14β-hydroxy-17β-((5-(3-aminopropyl)-isoxazol-3-yl))androstane;
3β-hydroxy-5β-10β-methyl-13β-methyl-14β-hydroxy-17β-((5-(3-aminopropyl)-isoxazol-3-yl)-ethyl)androstane;
3β-hydroxy-5β-10β-methyl-13β-methyl-14β-hydroxy-17β-(5-(2-aminoethyl)-isoxazol-3-yl)-ethyl)androstane; and
3β-hydroxy-5β-10β-methyl-13β-methyl-14β-hydroxy-17β-(5-(2-aminomethyl)-isoxazol-3-yl)-ethenyl)androstane.
7. Compounds according to claim 1 , wherein the pharmaceutically acceptable salt is selected from chloride, bromide, sulfate, phosphate, nitrate, fumarate, succinate, oxalate, malate, tartrate, maleate, citrate, methanesulfonate, or benzoate.
8. A pharmaceutical composition comprising one or more of the compounds of claim 1 , in combination with at least one pharmaceutically acceptable vehicle and/or excipient.
9. A pharmaceutical composition according to claim 8 , formulated for inhalation, oral administration, intravenous injection, or intramuscular injection.
10. A pharmaceutical composition according to claim 8 , further comprising one or more therapeutically active ingredients selected from the group consisting of ACE inhibitors, AIRBs, diuretics, Ca channel blockers, b blockers, digitalis, NO donors, vasodilators, SERCA2a stimulators, neprilisin (NEP) inhibitors, myosin filament activators, recombinant relaxin-2 mediators, recombinant NP protein, activators of the soluble Guanylate Cyclase (sGC), beta-arrestin ligand of Angiotensin II receptor and any combination thereof.
11. A pharmaceutical composition according to claim 10 , wherein said diuretic, is selected among furosemide, bumetanide, torasemide, metolazone, an aldosterone antagonist, and thiazide diuretics.
12. A pharmaceutical composition according to claim 10 , wherein said ACE inhibitor is Lisinopril or Ramipril.
13. A pharmaceutical composition according to claim 10 , wherein said Angiotensin H receptor blocker is valsartan, candesartan, olmesartan, telmisartan or losartan.
14. A pharmaceutical composition according to claim 10 , wherein said Angiotensin receptor/neprilysin inhibitor is sacubitril.
15. A pharmaceutical composition according to claim 10 , wherein said Beta-blocker is carvedilol or metoprolol.
16. A pharmaceutical composition according to claim 10 , wherein said Vasodilator is Hydralazine, Hydralazine combined with isosorbide dinitrate, nitrates, amlodipine, felodipine, or non-dihydropyridines.
17. A pharmaceutical composition according to claim 10 , wherein said agent for the treatment of heart failure is selected from Digoxin, entresto, omecantiv, serelaxin, ularitide, or levosimendan.
18. A method of treating or preventing a cardiovascular disorder in an individual, the method comprising the steps of:
(1) providing an individual having a cardiovascular disorder;
(2) measuring one or more indicators of cardiovascular disorders selected from the group consisting of Pulmonary Capillary Wedge Pressure (PCWP), dyspnea, peripheral and pulmonary venous congestion, urinary volume, exercise capacity, serum biomarker NT-proBNP, high sensitive cardiac Troponin (hs-cTnT), heart tissue damage, reduced exercise tolerance, renal insufficiency, oliguria, orthopnea, paroxysmal nocturnal dyspnea, tachypnea, ankle swelling, elevated jugular venous pressure, and any combination thereof; and
(3) administering to the individual a therapeutically effective amount of a pharmaceutical composition comprising one or more of the compounds of claim 1 whereby an improvement in the one or more indicators indicates treatment or prevention of the cardiovascular disorder in the individual.
19. A method of treating an individual having heart failure, the method comprising the steps of:
(1) providing an individual having heart failure;
(2) measuring one or more indicators of heart failure selected from the group consisting of Pulmonary Capillary Wedge Pressure (PCWP), dyspnea, peripheral and pulmonary venous congestion, urinary volume, exercise capacity, serum biomarker NT-proBNP, high sensitive cardiac Troponin (hs-cTnT), heart tissue damage, reduced exercise tolerance, renal insufficiency, oliguria, orthopnea, paroxysmal nocturnal dyspnea, tachypnea, ankle swelling, elevated jugular venous pressure, and any combination thereof; and
(3) administering to the individual a therapeutically effective amount of a pharmaceutical composition comprising one or more of the compounds of claim 1 whereby an improvement in the one or more indicators indicates treatment of heart failure in the individual.
20. The method of claim 19 , wherein heart failure is acute or chronic.